Aroa Biosurgery Limited, a regenerative medicine company, engages in the developing, manufacturing, and selling of medical devices for wound and tissue repair using extracellular matrix (ECM) technology in the United States and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$1.15|
|52 Week High||AU$0.97|
|52 Week Low||AU$1.43|
|1 Month Change||8.49%|
|3 Month Change||-2.95%|
|1 Year Change||-13.21%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-14.82%|
Recent News & Updates
Here's What Analysts Are Forecasting For Aroa Biosurgery Limited (ASX:ARX) After Its Annual Results
Investors in Aroa Biosurgery Limited ( ASX:ARX ) had a good week, as its shares rose 6.2% to close at AU$1.20 following...
|ARX||AU Biotechs||AU Market|
Return vs Industry: ARX underperformed the Australian Biotechs industry which returned 2.5% over the past year.
Return vs Market: ARX underperformed the Australian Market which returned 21.3% over the past year.
Stable Share Price: ARX is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: ARX's weekly volatility (6%) has been stable over the past year.
About the Company
Aroa Biosurgery Limited, a regenerative medicine company, engages in the developing, manufacturing, and selling of medical devices for wound and tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobia for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; and Reinforced Bioscaffolds, a surgical product for use in ventral hernia repair and abdominal wall reconstruction. The company was incorporated in 2007 and is headquartered in Auckland, New Zealand.
Aroa Biosurgery Fundamentals Summary
|ARX fundamental statistics|
Is ARX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ARX income statement (TTM)|
|Cost of Revenue||NZ$6.82m|
Last Reported Earnings
Mar 31, 2021
Next Earnings Date
Oct 27, 2021
|Earnings per share (EPS)||-0.056|
|Net Profit Margin||-85.98%|
How did ARX perform over the long term?See historical performance and comparison
Is Aroa Biosurgery undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ARX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ARX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ARX is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.
PE vs Market: ARX is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ARX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ARX is overvalued based on its PB Ratio (7x) compared to the AU Biotechs industry average (5x).
How is Aroa Biosurgery forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ARX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: ARX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ARX's is expected to become profitable in the next 3 years.
Revenue vs Market: ARX's revenue (36.4% per year) is forecast to grow faster than the Australian market (5.3% per year).
High Growth Revenue: ARX's revenue (36.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ARX is forecast to be unprofitable in 3 years.
How has Aroa Biosurgery performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: ARX is currently unprofitable.
Growing Profit Margin: ARX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if ARX's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare ARX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ARX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (48%).
Return on Equity
High ROE: ARX has a negative Return on Equity (-32.84%), as it is currently unprofitable.
How is Aroa Biosurgery's financial position?
Financial Position Analysis
Short Term Liabilities: ARX's short term assets (NZ$48.7M) exceed its short term liabilities (NZ$15.3M).
Long Term Liabilities: ARX's short term assets (NZ$48.7M) exceed its long term liabilities (NZ$5.9M).
Debt to Equity History and Analysis
Debt Level: ARX's debt to equity ratio (17%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if ARX's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ARX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ARX has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 21.8% each year.
What is Aroa Biosurgery current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ARX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ARX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ARX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ARX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ARX's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Dr. Brian Ward, B.V.Sc, MBA(dist) has been Executive Director at Aroa Biosurgery Limited since September 21, 2007 and serves as its Managing Director and Chief Executive Officer. Dr. Ward is founded Mesynt...
CEO Compensation Analysis
Compensation vs Market: Brian's total compensation ($USD1.23M) is above average for companies of similar size in the Australian market ($USD552.88K).
Compensation vs Earnings: Insufficient data to compare Brian's compensation with company performance.
Experienced Board: ARX's board of directors are considered experienced (6.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.9%.
Aroa Biosurgery Limited's employee growth, exchange listings and data sources
- Name: Aroa Biosurgery Limited
- Ticker: ARX
- Exchange: ASX
- Founded: 2007
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$393.142m
- Shares outstanding: 341.86m
- Website: https://aroabio.com
Number of Employees
- Aroa Biosurgery Limited
- 64 Richard Pearse Drive
- Airport Oaks
- New Zealand
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/25 16:53|
|End of Day Share Price||2021/10/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.